An Ohio State University study finds that many people lack crucial information about human papillomavirus transmission and ...

Q4 2024 Earnings Call Transcript March 20, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as ...

Importantly, our norovirus oral vaccine candidate has shown that it induces mucosal and systemic immune ... manufacture it for clinical use. On our HPV vaccine, we have additional preclinical ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs ... in a human challenge model, and elicited mucosal and systemic immunity in older adults.

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 ...

Persistent viral infections such as Human Papillomavirus (HPV). * Chronic irritation from sharp teeth ... and this stays in contact with oral mucosa or tissue that penetrates the body, causing ...